The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
And now a new set of shares. Things are moving.
Helium One Global Ltd (AIM:HE1) ("Helium One" or "the Company") announces that it has received notice to exercise warrants over a total of 1,560,229 Ordinary Shares (the "Warrant Shares") at a price of 2.84 pence per share.
Application will be made for the admission of the Warrant Shares to trading on AIM ("Admission"). The Warrant Shares will rank pari passu with the existing Ordinary Shares and it is expected that Admission will become effective at 8.00 a.m. on 6 June 2022.
This should happen today. And maybe we’ll find out who to:
Helium One has issued 2,077,284 new ordinary shares of no par value ("Ordinary Shares") to multiple service providers in lieu of cash payment (the "New Shares"). Application will be made for the admission of the New Shares to trading on AIM ("Admission"). The New Shares will rank pari passu with the existing Ordinary Shares and it is expected that Admission will become effective at 8.00 a.m. on 30 May 2022.
Looks like a list of those presenting at the session to me. https://www.abstractsonline.com/pp8/#!/10476/presentation/10405
In BG’s latest Ted Talk that they mention there at the start, he begins his piece by referencing fire fighting. Terminology used by Synairgen in the past when they describe what the product does.
Yes, 28th. It’s in the same RNS…
The validation of the PROmate® COVID-19 2G test follows the UK approval of the Company's COVID-19 genesig® Real-Time PCR test under the CTDA, as announced on 26 November 2021. In addition, as previously announced, Novacyt's PROmate® COVID-19 1G Real-Time PCR test, currently being supplied to the NHS under a National Microbiology Framework, remains on the temporary protocol list (due to expire on 28 February 2022) and the Company awaits further updates on an additional seven products submitted to the CTDA across its COVID-19 testing portfolio.
Apparently ‘the variant that wasn’t’
https://www.nature.com/articles/d41586-022-00149-9
See LSE investor webinar 22nd Oct 2021. Time code: 28:10. A question is asked about Mitchel drilling. DM responds by saying (amongst other things such as operational difficulties) “I’m very happy with Mitchell drilling, it didn’t work out, we’re both fine now and I wish them well in the future”
Very much confirming they are now looking to appoint a new drilling company.
Thanks for the link. Very insightful. Bring on early 2022 for more on this:
“The poster included the following data:
• SNG001 potently reduced virus to undetectable levels following infection of cells with ‘Wuhan-like’ SARS-CoV-2, Alpha, Beta or Gamma variants.
• SNG001 achieved 99% inhibition (IC99) at concentrations of 5.4, 17.7, 11.0 and 7.9 IU/mL respectively.”
Potential numbers in this report:
https://mcusercontent.com/d9ebd7c1aa0f3dbc5fab42eca/files/593f6711-7b6a-f49a-bde2-603b15ba1a2f/AlienMetals_24_11_2021_FINAL_BG.01.pdf